These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 37119510)

  • 1. Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome.
    Stone JK; Mehta NA; Singh H; El-Matary W; Bernstein CN
    Fam Cancer; 2023 Oct; 22(4):413-422. PubMed ID: 37119510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
    Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
    Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
    Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of familial adenomatous polyposis and MUTYH-associated polyposis; new insights.
    Aelvoet AS; Buttitta F; Ricciardiello L; Dekker E
    Best Pract Res Clin Gastroenterol; 2022; 58-59():101793. PubMed ID: 35988966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention in familial adenomatous polyposis.
    Kim B; Giardiello FM
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):607-22. PubMed ID: 22122775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients.
    Sample DC; Samadder NJ; Pappas LM; Boucher KM; Samowitz WS; Berry T; Westover M; Nathan D; Kanth P; Byrne KR; Burt RW; Neklason DW
    BMC Gastroenterol; 2018 Jul; 18(1):115. PubMed ID: 30012100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial adenomatous polyposis.
    Half E; Bercovich D; Rozen P
    Orphanet J Rare Dis; 2009 Oct; 4():22. PubMed ID: 19822006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary colorectal cancer syndromes.
    Strate LL; Syngal S
    Cancer Causes Control; 2005 Apr; 16(3):201-13. PubMed ID: 15947872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprevention Considerations in Patients with Hereditary Colorectal Cancer Syndromes.
    Macaron C; Mankaney GN; Haider M; Mouchli M; Hurley K; Burke CA
    Gastrointest Endosc Clin N Am; 2022 Jan; 32(1):131-146. PubMed ID: 34798982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of colorectal cancer in high-risk populations: the increasing role for endoscopy and chemoprevention in FAP and HNPCC.
    Lynch PM
    Digestion; 2007; 76(1):68-76. PubMed ID: 17947820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoscopic Surveillance and Treatment of Upper GI Tract Lesions in Patients with Familial Adenomatous Polyposis-A New Perspective on an Old Disease.
    Paszkowski J; Samborski P; Kucharski M; Cwaliński J; Banasiewicz T; Pławski A
    Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC): a review of clinical, genetic and therapeutic aspects.
    Soravia C; Bapat B; Cohen Z
    Schweiz Med Wochenschr; 1997 Apr; 127(16):682-90. PubMed ID: 9140167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention in familial adenomatous polyposis: past, present and future.
    Kemp Bohan PM; Mankaney G; Vreeland TJ; Chick RC; Hale DF; Cindass JL; Hickerson AT; Ensley DC; Sohn V; Clifton GT; Peoples GE; Burke CA
    Fam Cancer; 2021 Jan; 20(1):23-33. PubMed ID: 32507936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention in hereditary colorectal cancer syndromes.
    Hawk E; Lubet R; Limburg P
    Cancer; 1999 Dec; 86(11 Suppl):2551-63. PubMed ID: 10630181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate.
    Septer S; Lawson CE; Anant S; Attard T
    Fam Cancer; 2016 Jul; 15(3):477-85. PubMed ID: 27056662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).
    Burn J; Mathers J; Bishop DT
    Recent Results Cancer Res; 2013; 191():157-83. PubMed ID: 22893205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cohorts with familial disposition for colon cancers in chemoprevention trials.
    Burt RW
    J Cell Biochem Suppl; 1996; 25():131-5. PubMed ID: 9027609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.
    Thun MJ; Henley SJ; Patrono C
    J Natl Cancer Inst; 2002 Feb; 94(4):252-66. PubMed ID: 11854387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
    Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.